Differential knockdown of δ-opioid receptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA

Lucia Negri, Roberta Lattanzi, A. Borsodi, Geza Toth, Severo Salvadori

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Two antisense oligodeoxynucleotides (A-ODN), targeting δ-opioid receptor mRNA (DOR) and two mismatch ODN sequences (mODN) were continuously infused for 24 days into the lateral brain ventricles of Wistar rats. The density of δ-opioid receptors in rat brain homogenates was measured by saturation binding experiments using four selective ligands, two agonists ([D-Ala2, Glu4]-deltorphin and DPDPE) and two antagonists (Dmt-Tic-OH and naltrindole), and by immunoblotting SDS solubilized receptor protein. In brain membranes of mODN or saline-infused rats, the rank order of δ-opioid receptor density, calculated by B(max) values of the four δ-opioid receptor ligands, was: [D-Ala2, Glu4]deltorphin ≃ Dmt-Tic-OH ≃ naltrindole (86-118 fmol/mg protein) > DPDPE (73.6 ± 6.3 fmol/mg protein). At the end of the 24 day infusion of A-ODN targeting DOR nucleotide sequence 280-299 (A-ODN280-299), the B(max) of DPDPE (62.4 ± 3.2 fmol/mg protein) was significantly higher than that of Dmt-Tic-OH (31.5 ± 3.9 fmol/mg protein). Moreover, both the K(d) value for DPDPE saturation binding and the K(i) value for Dmt-Tic-OH displacement by DPDPE were halved. In contrast, an A-ODN treatment targeting exon 3 (A-ODN741-760) decreased the specific binding of [D-Ala2, Glu4]deltorphin and Dmt-Tic-OH significantly less (67%-81%) than the binding of DPDPE (53%), without changes in DPDPE K(i) and K(D) values. No A-ODN treatment modified the specific binding of the μ-opioid agonist DAMGO and of the k-selective opioid receptor ligand U69593. On the Western blot of solubilized striatum proteins, A-ODN280-299 and A-ODN741-760 downregulated the levels of the DOR protein, whereas the corresponding mODN were inactive. The 24-day infusion of A-ODN280-299 inhibited the rat locomotor response to [D-Ala2, Glu4]deltorphin but not to DPDPE. Intracerebroventricular (i.c.v.) infusion of A-ODN741-760 reduced the locomotor responses to both δ-opioid receptor agonists, whereas mODN infusion never affected agonist potencies. In conclusion, these results demonstrate that 24-day continuous i.c.v. infusion of A-ODN targeting the nucleotide sequence 280-299 of DOR can differentially knockdown δ1 and δ2 binding sites in the rat brain.

Original languageEnglish
Pages (from-to)203-211
Number of pages9
JournalAntisense and Nucleic Acid Drug Development
Volume9
Issue number2
Publication statusPublished - 1999

Fingerprint

D-Penicillamine (2,5)-Enkephalin
Oligodeoxyribonucleotides
Opioid Receptors
Rats
Brain
Messenger RNA
naltrindole
Nucleotides
Intraventricular Infusions
Proteins
Ligands
Ala(2)-MePhe(4)-Gly(5)-enkephalin
Lateral Ventricles
Staphylococcal Protein A
Immunoblotting
Opioid Analgesics
Wistar Rats
Exons
Down-Regulation
Western Blotting

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

Differential knockdown of δ-opioid receptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA. / Negri, Lucia; Lattanzi, Roberta; Borsodi, A.; Toth, Geza; Salvadori, Severo.

In: Antisense and Nucleic Acid Drug Development, Vol. 9, No. 2, 1999, p. 203-211.

Research output: Contribution to journalArticle

@article{486382e227584c1a9c108a683d80cfad,
title = "Differential knockdown of δ-opioid receptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA",
abstract = "Two antisense oligodeoxynucleotides (A-ODN), targeting δ-opioid receptor mRNA (DOR) and two mismatch ODN sequences (mODN) were continuously infused for 24 days into the lateral brain ventricles of Wistar rats. The density of δ-opioid receptors in rat brain homogenates was measured by saturation binding experiments using four selective ligands, two agonists ([D-Ala2, Glu4]-deltorphin and DPDPE) and two antagonists (Dmt-Tic-OH and naltrindole), and by immunoblotting SDS solubilized receptor protein. In brain membranes of mODN or saline-infused rats, the rank order of δ-opioid receptor density, calculated by B(max) values of the four δ-opioid receptor ligands, was: [D-Ala2, Glu4]deltorphin ≃ Dmt-Tic-OH ≃ naltrindole (86-118 fmol/mg protein) > DPDPE (73.6 ± 6.3 fmol/mg protein). At the end of the 24 day infusion of A-ODN targeting DOR nucleotide sequence 280-299 (A-ODN280-299), the B(max) of DPDPE (62.4 ± 3.2 fmol/mg protein) was significantly higher than that of Dmt-Tic-OH (31.5 ± 3.9 fmol/mg protein). Moreover, both the K(d) value for DPDPE saturation binding and the K(i) value for Dmt-Tic-OH displacement by DPDPE were halved. In contrast, an A-ODN treatment targeting exon 3 (A-ODN741-760) decreased the specific binding of [D-Ala2, Glu4]deltorphin and Dmt-Tic-OH significantly less (67{\%}-81{\%}) than the binding of DPDPE (53{\%}), without changes in DPDPE K(i) and K(D) values. No A-ODN treatment modified the specific binding of the μ-opioid agonist DAMGO and of the k-selective opioid receptor ligand U69593. On the Western blot of solubilized striatum proteins, A-ODN280-299 and A-ODN741-760 downregulated the levels of the DOR protein, whereas the corresponding mODN were inactive. The 24-day infusion of A-ODN280-299 inhibited the rat locomotor response to [D-Ala2, Glu4]deltorphin but not to DPDPE. Intracerebroventricular (i.c.v.) infusion of A-ODN741-760 reduced the locomotor responses to both δ-opioid receptor agonists, whereas mODN infusion never affected agonist potencies. In conclusion, these results demonstrate that 24-day continuous i.c.v. infusion of A-ODN targeting the nucleotide sequence 280-299 of DOR can differentially knockdown δ1 and δ2 binding sites in the rat brain.",
author = "Lucia Negri and Roberta Lattanzi and A. Borsodi and Geza Toth and Severo Salvadori",
year = "1999",
language = "English",
volume = "9",
pages = "203--211",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Differential knockdown of δ-opioid receptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA

AU - Negri, Lucia

AU - Lattanzi, Roberta

AU - Borsodi, A.

AU - Toth, Geza

AU - Salvadori, Severo

PY - 1999

Y1 - 1999

N2 - Two antisense oligodeoxynucleotides (A-ODN), targeting δ-opioid receptor mRNA (DOR) and two mismatch ODN sequences (mODN) were continuously infused for 24 days into the lateral brain ventricles of Wistar rats. The density of δ-opioid receptors in rat brain homogenates was measured by saturation binding experiments using four selective ligands, two agonists ([D-Ala2, Glu4]-deltorphin and DPDPE) and two antagonists (Dmt-Tic-OH and naltrindole), and by immunoblotting SDS solubilized receptor protein. In brain membranes of mODN or saline-infused rats, the rank order of δ-opioid receptor density, calculated by B(max) values of the four δ-opioid receptor ligands, was: [D-Ala2, Glu4]deltorphin ≃ Dmt-Tic-OH ≃ naltrindole (86-118 fmol/mg protein) > DPDPE (73.6 ± 6.3 fmol/mg protein). At the end of the 24 day infusion of A-ODN targeting DOR nucleotide sequence 280-299 (A-ODN280-299), the B(max) of DPDPE (62.4 ± 3.2 fmol/mg protein) was significantly higher than that of Dmt-Tic-OH (31.5 ± 3.9 fmol/mg protein). Moreover, both the K(d) value for DPDPE saturation binding and the K(i) value for Dmt-Tic-OH displacement by DPDPE were halved. In contrast, an A-ODN treatment targeting exon 3 (A-ODN741-760) decreased the specific binding of [D-Ala2, Glu4]deltorphin and Dmt-Tic-OH significantly less (67%-81%) than the binding of DPDPE (53%), without changes in DPDPE K(i) and K(D) values. No A-ODN treatment modified the specific binding of the μ-opioid agonist DAMGO and of the k-selective opioid receptor ligand U69593. On the Western blot of solubilized striatum proteins, A-ODN280-299 and A-ODN741-760 downregulated the levels of the DOR protein, whereas the corresponding mODN were inactive. The 24-day infusion of A-ODN280-299 inhibited the rat locomotor response to [D-Ala2, Glu4]deltorphin but not to DPDPE. Intracerebroventricular (i.c.v.) infusion of A-ODN741-760 reduced the locomotor responses to both δ-opioid receptor agonists, whereas mODN infusion never affected agonist potencies. In conclusion, these results demonstrate that 24-day continuous i.c.v. infusion of A-ODN targeting the nucleotide sequence 280-299 of DOR can differentially knockdown δ1 and δ2 binding sites in the rat brain.

AB - Two antisense oligodeoxynucleotides (A-ODN), targeting δ-opioid receptor mRNA (DOR) and two mismatch ODN sequences (mODN) were continuously infused for 24 days into the lateral brain ventricles of Wistar rats. The density of δ-opioid receptors in rat brain homogenates was measured by saturation binding experiments using four selective ligands, two agonists ([D-Ala2, Glu4]-deltorphin and DPDPE) and two antagonists (Dmt-Tic-OH and naltrindole), and by immunoblotting SDS solubilized receptor protein. In brain membranes of mODN or saline-infused rats, the rank order of δ-opioid receptor density, calculated by B(max) values of the four δ-opioid receptor ligands, was: [D-Ala2, Glu4]deltorphin ≃ Dmt-Tic-OH ≃ naltrindole (86-118 fmol/mg protein) > DPDPE (73.6 ± 6.3 fmol/mg protein). At the end of the 24 day infusion of A-ODN targeting DOR nucleotide sequence 280-299 (A-ODN280-299), the B(max) of DPDPE (62.4 ± 3.2 fmol/mg protein) was significantly higher than that of Dmt-Tic-OH (31.5 ± 3.9 fmol/mg protein). Moreover, both the K(d) value for DPDPE saturation binding and the K(i) value for Dmt-Tic-OH displacement by DPDPE were halved. In contrast, an A-ODN treatment targeting exon 3 (A-ODN741-760) decreased the specific binding of [D-Ala2, Glu4]deltorphin and Dmt-Tic-OH significantly less (67%-81%) than the binding of DPDPE (53%), without changes in DPDPE K(i) and K(D) values. No A-ODN treatment modified the specific binding of the μ-opioid agonist DAMGO and of the k-selective opioid receptor ligand U69593. On the Western blot of solubilized striatum proteins, A-ODN280-299 and A-ODN741-760 downregulated the levels of the DOR protein, whereas the corresponding mODN were inactive. The 24-day infusion of A-ODN280-299 inhibited the rat locomotor response to [D-Ala2, Glu4]deltorphin but not to DPDPE. Intracerebroventricular (i.c.v.) infusion of A-ODN741-760 reduced the locomotor responses to both δ-opioid receptor agonists, whereas mODN infusion never affected agonist potencies. In conclusion, these results demonstrate that 24-day continuous i.c.v. infusion of A-ODN targeting the nucleotide sequence 280-299 of DOR can differentially knockdown δ1 and δ2 binding sites in the rat brain.

UR - http://www.scopus.com/inward/record.url?scp=0033066793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033066793&partnerID=8YFLogxK

M3 - Article

C2 - 10355826

AN - SCOPUS:0033066793

VL - 9

SP - 203

EP - 211

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 2

ER -